Cargando…

Fragile x syndrome and autism: from disease model to therapeutic targets

Autism is an umbrella diagnosis with several different etiologies. Fragile X syndrome (FXS), one of the first identified and leading causes of autism, has been modeled in mice using molecular genetic manipulation. These Fmr1 knockout mice have recently been used to identify a new putative therapeuti...

Descripción completa

Detalles Bibliográficos
Autores principales: Dölen, Gül, Bear, Mark F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164025/
https://www.ncbi.nlm.nih.gov/pubmed/21547712
http://dx.doi.org/10.1007/s11689-009-9015-x
_version_ 1782211005215932416
author Dölen, Gül
Bear, Mark F.
author_facet Dölen, Gül
Bear, Mark F.
author_sort Dölen, Gül
collection PubMed
description Autism is an umbrella diagnosis with several different etiologies. Fragile X syndrome (FXS), one of the first identified and leading causes of autism, has been modeled in mice using molecular genetic manipulation. These Fmr1 knockout mice have recently been used to identify a new putative therapeutic target, the metabotropic glutamate receptor 5 (mGluR5), for the treatment of FXS. Moreover, mGluR5 signaling cascades interact with a number of synaptic proteins, many of which have been implicated in autism, raising the possibility that therapeutic targets identified for FXS may have efficacy in treating multiple other causes of autism.
format Online
Article
Text
id pubmed-3164025
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-31640252011-10-18 Fragile x syndrome and autism: from disease model to therapeutic targets Dölen, Gül Bear, Mark F. J Neurodev Disord Article Autism is an umbrella diagnosis with several different etiologies. Fragile X syndrome (FXS), one of the first identified and leading causes of autism, has been modeled in mice using molecular genetic manipulation. These Fmr1 knockout mice have recently been used to identify a new putative therapeutic target, the metabotropic glutamate receptor 5 (mGluR5), for the treatment of FXS. Moreover, mGluR5 signaling cascades interact with a number of synaptic proteins, many of which have been implicated in autism, raising the possibility that therapeutic targets identified for FXS may have efficacy in treating multiple other causes of autism. Springer US 2009-05-12 2009-06 /pmc/articles/PMC3164025/ /pubmed/21547712 http://dx.doi.org/10.1007/s11689-009-9015-x Text en © Springer Science+Business Media, LLC 2009
spellingShingle Article
Dölen, Gül
Bear, Mark F.
Fragile x syndrome and autism: from disease model to therapeutic targets
title Fragile x syndrome and autism: from disease model to therapeutic targets
title_full Fragile x syndrome and autism: from disease model to therapeutic targets
title_fullStr Fragile x syndrome and autism: from disease model to therapeutic targets
title_full_unstemmed Fragile x syndrome and autism: from disease model to therapeutic targets
title_short Fragile x syndrome and autism: from disease model to therapeutic targets
title_sort fragile x syndrome and autism: from disease model to therapeutic targets
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164025/
https://www.ncbi.nlm.nih.gov/pubmed/21547712
http://dx.doi.org/10.1007/s11689-009-9015-x
work_keys_str_mv AT dolengul fragilexsyndromeandautismfromdiseasemodeltotherapeutictargets
AT bearmarkf fragilexsyndromeandautismfromdiseasemodeltotherapeutictargets